Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Tuesday, November 28, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, Inc. has announced the grant of an inducement award under Nasdaq Listing Rule 5635(c)(4). This award supports the company's efforts in advancing its proprietary ARCUS platform for in vivo gene editing therapies. The announcement highlights the company's commitment to sophisticated gene edits, including insertion, excision, and elimination.
Price reaction · baseline $11.865 (2023-11-28T17:54:00.000Z) · hit during market hours · 1 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
+3.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is advancing gene editing technology.
  • The company is utilizing its proprietary ARCUS platform.
  • The grant of inducement award supports its Nasdaq listing.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Nov. 28, 2023– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,

Frequently Asked Questions

What is the inducement award announced by Precision BioSciences?

The inducement award supports Precision BioSciences' efforts under Nasdaq Listing Rule 5635(c)(4).

What platform does Precision BioSciences use for gene editing?

Precision BioSciences utilizes its proprietary ARCUS platform for gene editing.

What types of gene edits can the ARCUS platform perform?

The ARCUS platform can perform gene insertion, excision, and elimination.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing Nasdaq ARCUS platform
Last updated: Nov 28, 2023

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →